At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 99 enrolled
Drug / intervention
BI 1744 +3 moredrug
Likely dose
Foradil 12 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil Iin Patients With Chronic Obstructive Pulmonary Disease
In Brief
A Phase 3 clinical trial evaluating BI 1744, bi1744, and 2 other interventions for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 99 participants across 11 sites.
Detailed Summary
The study is intended to characterize the lung function profile of BI1744 in COPD patients where patients will perform pulmonary function tests at regular intervals for 24 hours at the end of a 6 week treatment period. Each patient will receive all four treatments.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2009
First PostedJul 2009
Primary CompletionApr 2010
TodayJul 2026
First PostedJul 2, 2009
Enrollment StartJun 1, 2009
Primary CompletionApr 1, 2010
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 17 years ago
Interventions
BI 1744drug
BI1744 Respimat Med Dose Once Daily
bi1744drug
1744 low dose
Placebodrug
Placebo Respimat and Foradil Placebo
Foradildrug
Foradil 12 mcg twice daily and Placebo Respimat